Navigation Links
Korean Food and Drug Administration Approval for ActiPatch Achieved

FREDERICK, Md., Oct. 16 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the by the Korean Food and Drug Administration has cleared ActiPatch for sale in Korea.

"We have been working closely with our distributor, YoungKwangSa Co., Ltd., to achieve the approval of the Korean F.D.A. Having worked so diligently to obtain the approvals, we are confident that YoungKwangSa is now poised to successfully launch ActiPatch in the Korean market. We expect to ship the initial stock order within the next 15 days," said Andrew Whelan, President of BioElectronics Corporation.

Marshal Nam of YoungKwangSa said "We are pleased to have achieved the clearance from the Korean FDA to begin importing the ActiPatch device. It was a long process and we worked cooperatively with BioElectronics Corporation to obtain the necessary approvals. We are excited to represent ActiPatch in Korea and expect to have a strong business relationship with BioElectronics Corporation for many years."

About YoungKwangSa Co., Ltd.:

Founded in 1971, YoungKwangSa has provided medical professionals in Korea with the most state-of-the art medical devices available. To learn more about YoungKwangSa please visit

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

SOURCE BioElectronics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Brady Corp. acquires Korean counterpart
2. Third Wave seeks approval of Cystic Fibrosis test
3. Kyron wins FDA approval for brain imaging technology
4. SGI receives court approval for bankruptcy motions
5. FDA programs encourage and expedite drug development and approval
6. UW-Stevens Point Professor Receives Patent Approval For New Technology
7. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
8. 140-Fold Increase of Protein Achieved in Pichia Fermentation
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):